Lv21
160 积分 2024-10-10 加入
Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans
1小时前
待确认
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
13天前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
14天前
已完结
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics
26天前
已完结
Translational Approaches for Human Pharmacokinetics and Pharmacodynamics Prediction of Antibody-drug Conjugates: Bridging Complexity from Bench to Bedside
28天前
已完结
Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs
28天前
已完结
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors
1个月前
已关闭
A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level
1个月前
已完结
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology
1个月前
已完结
An FDA oncology analysis of immune activating products and first-in-human dose selection
1个月前
已完结
皖公网安备34019202002308
